Amylx Pharmaceuticals Inc vs Teucrium Wheat Fund — how do they compare? Amylx Pharmaceuticals Inc trades at $23.68 (market cap $2.64B), while Teucrium Wheat Fund trades at $24.42. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals.
| AMLX | WEAT | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $24.19 | $26.00 |
52-Week Low | $7.82 | $19.88 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
WEAT, the Teucrium Wheat Fund, trades at $24.42, up 1.71% today, with a bullish technical signal from moving averages. Recent news highlights a 9.9% monthly gain, driven by wheat price increases and USDA production cuts. The ETF's performance is closely tied to agricultural commodity markets and inflation trends.
Outlook remains influenced by supply dynamics and inflation; opportunities exist from sustained commodity strength, but risks include weather volatility and economic shifts that could pressure wheat prices and ETF returns.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →